Malvern gene therapy developer to acquire publicly traded Boston company

Ocugen Corp., a Malvern-based gene therapy and biopharmaceutical company developing new treatments for rare and underserved eye diseases, entered into a merger agreement Monday with Histogenics Corp., a publicly traded company based in Boston Under the terms of the stock-for-stock agreement, the stockholders of Ocugen will own about 90 percent of Histogenics’ outstanding common stock once the deal closes. Shareholders of Histogenics — which began Monday with a market cap of $10.5 million —…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news